DreamCIS, Inc. (KOSDAQ:223250)
South Korea · Delayed Price · Currency is KRW 3,395.00
+95.00 (2.88%)
At close: Sep 4, 2026
DreamCIS Revenue
DreamCIS had revenue of 20.01B KRW in the quarter ending June 30, 2026, with 20.54% growth. This brings the company's revenue in the last twelve months to 73.28B, up 14.96% year-over-year. In the year 2025, DreamCIS had annual revenue of 66.63B with 13.60% growth.
Revenue (ttm)
73.28B
Revenue Growth
+14.96%
P/S Ratio
1.14
Revenue / Employee
187.42M
Employees
411
Market Cap
83.52B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 66.63B | 7.98B | 13.60% |
| Dec 31, 2024 | 58.65B | 10.81B | 22.59% |
| Dec 31, 2023 | 47.84B | 8.97B | 23.08% |
| Dec 31, 2022 | 38.87B | 12.72B | 48.64% |
| Dec 31, 2021 | 26.15B | 2.66B | 11.34% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| HLB bioStep | 73.96B |
| C&R Research | 63.55B |
| DT&CRO CO. | 47.77B |
| Kolmar BioTech | 40.30B |
| BioInfra | 25.62B |
| P&K Skin Research Center | 22.56B |
| Penetrium Bioscience | 9.74B |
| Ingenia Therapeutics | 7.42B |